# imRECIST (immune-modified RECIST)

Source: https://onco.cc/terms/imrecist/  
OnCo record `imrecist` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

imRECIST is a variant of the scan-measuring rules from atezolizumab trials that lets a response after apparent growth count, to capture benefit from immunotherapy that standard rules miss.

## Summary

Hodi and colleagues (Journal of Clinical Oncology 2018) applied immune-modified RECIST to atezolizumab trial data in lung, bladder and kidney cancer and melanoma. It allows a best response after progressive disease and changes how new and non-target lesions define progression. Compared with RECIST 1.1, best overall response was 1 to 2 percentage points higher, disease control 8 to 13 points higher and median progression-free survival 0.5 to 1.5 months longer. Progression defined only by new lesions was not associated with longer survival.

## Fields

- Kind: Term
- Last checked: 2026-11-04
- Also known as: imRECIST; immune-modified RECIST

## Sources

- Hodi et al., Immune-modified Response Evaluation Criteria In Solid Tumors (imRECIST) (J Clin Oncol 2018): https://doi.org/10.1200/jco.2017.75.1644

## Connected records

- terms: [Immune-related response criteria (irRC)](https://onco.cc/terms/irrc/), [iRECIST (response criteria for immunotherapy trials)](https://onco.cc/terms/irecist/), [RECIST](https://onco.cc/terms/recist/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)

---
JSON: https://onco.cc/api/v1/entities/imrecist.json